With an expanding range of pharmacological options and continuously evolving guidelines, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered substantial clinical and societal attention for their role in T2D and weight-management. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.